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Introduction:  Renal cell carcinoma epitomizes a diversified group of tumors which contributes more than
15,000 deaths annually worldwide. In spite of tremendous efforts to identify prognostic factors apart from
grade, histology and tumor size, they are not so obvious yet to fulfill the requirement. In this study, the
prognostic role of serum matrix metalloproteinase (MMP)-2, 9, and vascular endothelial growth factor
(VEGF) levels in patients with pre and postoperative renal cell carcinoma are evaluated to use as biomarker.
Patients and  methods:  A total of 100 patients with a diagnosis of renal cell carcinoma included in the study.
Additionally, hundred healthy kidney donors enrolled as control, serum MMP-2, MMP-9, and VEGF levels
were analyzed in the serum of post and preoperative patients and parallel in control serum samples by
ELISA method.
Result:  Most of the patients with RCC were found to have high concentrations of serum MMP-2,
MMP-9, and VEGF. The levels of MMP-2 in the serum of preoperative patients ranged from 627 to
1117 ng/ml (833.90 ±  111.91), postoperative MMP-2 range 302–913 (553.02 ±  150.08), control range
122–384 (228.33 ±  72.52). In MMP-9 pre-operative range 619–1233 (862.32 ±  119.77), post-operative
range 124–909 (552.88 ±  151.91) and control range 42–467 (245.44 ±  116.52 and in VEGF preoperative
range was 0.792–2.214 (1.35 ±  0.36), postoperative range was 0.315–1.917 (0.81 ±  0.46) and in control it
e observed that preoperative levels of all three markers, were significantly
toperative and control levels (P = 0.001) however, no any significant correla-
related with grade, stage, size, and type for MMP-2 and MMP-9, but VEGF
mparison.was 0.01–0.39 (0.10 ±  0.09). W
increased if compared with pos
tion found when the levels cor
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Conclusion:  The present data shows relevance and strong significant decrease in the level of MMP-2,
MMP-9, and VEGF after surgery, so they could use as biomarkers in early disease diagnosis and also in
monitoring disease recurrence.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open





























































































enal cell carcinoma (RCC) is also known as hypernephroma, which
s the cancer of the kidney and generally begins from very upper
ayer of the proximal convoluted tubule, which filters the blood to
emove waste products from the body. Nearly three to four percent
f all solid tumors represent RCC and, it is supposed to be the sixth
scorted reason of carcinoma linked fatality, owing to the lack of
herapeutic remedies for locally advanced or in case of metastatic
isease [1]. Tumors limited within renal parenchyma mostly favor
ve years survival rate in up to sixty to seventy percent cases, but
his is low considerably where metastases occurred outside renal
arenchyma, so restricting the tumor at its initial stage is the prime
arget these days as the disease is mostly resistant to chemotherapy
nd also to radiation therapy, only a few cases are seen to respond
ith immunotherapy. It is very piteous that no corroborated RCC
arker is known for detection of first-degree disease or the disease
ithout any symptoms in selected populations for the prognostic or
reatment effectiveness monitoring point of view [2]. High-quality
etection techniques are required for its preliminary identification
n an initial stage and for closely watching the recurrent tumors
o cop them in the preliminary phase after surgery either by total
r partial nephrectomy [3]. Several markers like CD44, VEGF and
lasma amyloid-alpha have been experimented as a prospective tool
or prognostic or indicative factors for RCC [4–8], though they
till need to validate in rigorous trials. It is still an urgent need of
CC tumor biomarker for detecting renal cell carcinoma in its early
tage. Biomarkers especially humoral tumor markers using blood
erum could be ideal for the routine checkup of RCC in scheduled
ollow-ups intended to perceive any progression. In this context, we
eviewed and observed some literature and local studies to presume
hat some markers like MMP-2, MMP-9 and, VEGF have potential
eatures which originate as well as facilitate the progression of RCC.
ndividually if we see, the (vascular endothelial growth factor) has a
ivotal role in couple of physiological process, in the development
f new blood, in embryo formation, skeletal growth, wound repair
ainly, VEGF is a leading cause of pathological angiogenesis and
esponsible for malignancies, inflammation, diabetic retinopathy,
heumatoid arthritis and many conditions [9]. VEGF is also respon-
ible in propagation and voyage of endothelial cells physiologically
s well as pathologically through binding with two congruent VEGF
eceptors of vascular endothelial cells (VEGF receptor-1 and 2)
nd is a glycoprotein of approximately 45 kDa. VEGF’s are mostly
een expressing in neutrophils, fibroblasts, epithelial cells, activated
acrophages, vascular smooth muscle cells which all are combinednd involved in renal cell activities and lead to renal cell carcinoma
hen influenced with overexpression of VEGF and other factors
10,11]. On the other hand, MMP (matrix metalloproteinase) is a





enerally does its actions by degrading macromolecules of the
xtracellular matrix and has around 28 members in the family, all
omprise different types of actions.
ll together they are responsible for remodeling of tissues and
n many physiological as well as pathological developments like
rthritis, cirrhosis, angiogenesis, tissue repair, morphogenesis etc.
MP-2 and MMP-9 are mostly considered and thought to be
esponsible in case of metastatic disease [12]. MMP and VEGF
re massively studied to enumerate their versatile role in angiogen-
sis as well as metastasis in cases of malignant tumors and also
n RCC. Furthermore, it is now also known that MMP and VEGF
re most active in the progression of the disease through sequential
teps like extravasations and intravasations [13]. MMPs generally
rbitrate basement membrane and extracellular matrix humiliation
uring the very early stage of tumor genesis, which usually con-
ributes to the development of a microenvironment that encourages
he tumor growth. MMPs are also active in the later stages of cancer
rogression in which they result in metastasis of the disease [14].
atest indications recommend that MMPs and VEGF are moreover
ignificant in the initial stage of tumor maturity until metastasis takes
lace. Serum level of MMP-2, MMP-9, and VEGF were reported
o be significantly elevated in tumor tissue and in the urine sample
rom patients with RCC [15,16]. But no such studies were reported
n our Indian population. Due to the aggressiveness of RCC, most
ases are presenting with metastatic disease, due to which patients
ould not find better survival and die in a very short time. Surgical
esection is the only management available at the time of diagno-
is but the devious nature of the disease is reflected by the rate of
he majority of recurrences after surgery. For this reason, the study
as designed to identify disease or recurrence potential patients at
n early stage by using biomarkers, which may help to prescribe
dditional therapy of anti-MMP-2, anti-MMP-9, and anti-VEGF at
xact time required for treatment, which is looking effective in the
mprovement of overall and progression-free survival of the patient.
or this purpose, the preoperative and postoperative serum level
f MMP-2, MMP-9, and VGEF in RCC patients are measure, and
imultaneously marker level has been seen in healthy controls also
nd compared. With the correlation of levels in pre vs. post vs. con-
rol, the levels checked against the stage, grade, size of the tumor and
ifferent types of RCC tumor to see if any correlation seen between
he levels and co-factors for more exploratory information.
n our knowledge, this is the first study from India about the level
f MMP-2, MMP-9, and VEGF in pre-operative and post-operative
enal cell carcinoma, for analyzing the pattern of increasing activ-
ties in conditions and to verify whether they may have potential
s biomarker in providing useful clinical information in recurrence
r having maximum probability of RCC. In the present study, we
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MMP-2, MMP-9 and VEGF in early prognosis of Renal cell carcin
aimed to determine MMP-2, MMP-9 and VEGF activity levels in
serum from patients with the Clear cell, Papillary, Chromophobe and
some other type of renal cell carcinoma using pre-coated MMP-2,
MMP-9, and VEGF kits.
Patients  and  methods
In this case-control study, 100 outpatients with histological and
related scan confirmation for renal cell carcinoma recruited between
January 2011 to May 2013 from the Outpatient Department of Urol-
ogy, Sanjay Gandhi Post Graduate Institute of Medical Sciences and
King George Medical College, Lucknow, India. Both these medical
institutes are renowned tertiary care multispecialty hospitals with
medical college facility in the northern part of India. The enrolled
patients included 71 male and 29 female with the mean age of 53
years (range 21–79). The patient recruited for the study had a pro-
gressive, inoperable histological confirmed renal cell carcinoma.
Before patient surgery, a full medical examination including chest
X-ray, abdominal–pelvic ultrasonography, computerized tomogra-
phy, bone scan and blood biochemistry was carried out. The patient
enrolled in the study after taking their consent on the proper guide-
lines of the ethics committee of King George’s Medical College,
Lucknow-India, ethics committee approved informed consent doc-
ument. All the patients enrolled in the study were having no any
other malignancy other than renal malignancy. They were in aver-
age ECOG status ≤2 and in better hepatic and bone marrow function.
Patient characteristics are summarized in Table 1.
The control group enrolled to compare the results between disease
and normal. For the purpose 100 healthy kidney donors selected after
tested against any malignancy or disease and they recruited from the
same outpatient departments The control group comprises healthy
kidney donors without any comorbidities. They also enrolled after
taking proper informed consent form. The mean age of recruited
control was 46, ranges between 24 to 71 years.
5 ml of venous blood collected from the patient immediately
(30 min ±  10 min) before their planned surgery of kidney, radical
nephrectomy or partial nephrectomy. Blood collected in EDTA
vacutainer and serum-separating tube II vacutainer and, stored at
−80 ◦C within 15 min of collection. Again after surgery 5 ml of
venous blood collected from the same patient within 48 h after the
surgery and, stored accordingly under the labeling of patient study
code as preoperative samples and postoperative samples. The con-
trol blood samples collected from healthy kidney donors and, stored
in the same manner as in RCC patients after labeling them as control
sample with their code identifier.
Determination  of  serum  matrixmetalloproteinase-2,  9  and  VEGF
levels  by  ELSA
Quantitative analysis of serum MMP-2, MMP-9, and VEGF has
been done by using commercial Human Puregene ELISA kits as per
the manufacturer’s instructions (Genetix Biotech Asia Pvt., Ltd.).
Briefly, Enzyme-Linked Immunosorbent Assay (ELISA) is a diag-
nostic tool which is now a day widely used in the medical sector.
It is working on the principle of antigen-antibody interaction in
which antigen from any specific sample is attached to the surface of
the kit, and an additional specific antibody is applied over the sur-
face which binds to the antigen. Finally, a substrate added, which






etectable signals as a change in the colour of the substrate. Work-
ng on the same principle our ELISA kits also based on a two-site
LISA sandwich format. Standards and serum samples incubated
n a microwell plate precoated with anti-MMP-2, anti-MMP-9 and,
nti-VEGF antibody.
t the start of laboratory work standardization of positive controls
known value samples) done as per the given protocol, after that in
rst 8 well which concludes a single row of 12 rows of ELISA kit
96 wells in total), controls transferred in increasing concentration.
rom the second row onward patient serum samples transferred in
uplicate (each patient sample kept in two wells), finally high puri-
ed IgG known as conjugate added in all wells and after that kit
ept for incubation as per protocol required time. MMP-2, MMP-9,
nd VEGF present in samples bound to their specific antibod-
es used in MMP-2, MMP-9, and VEGF kits. Extensive washing
hrough kit specific washing detergent used to remove non targeted
olecules which remain unattached on wells after that kits coated
ith peroxidise-labelled antibody and again incubated. Finally, the
eaction stopped using stop solution and the absorbance was read at
50 nm in a microtiter plate of ELISA Reader. Serum concentrations
f MMP-2, MMP-9, and VEGF obtained from the corresponding
tandard curves and values received in each case of pre-operative,
ost-operative cases and controls.
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Figure  1  A. Serum MMP-2 level in pre operative, post operative RCC patients and controls. B. Level difference of MMP-9 in pre, post operative
RCC patients and in controls. C. Comparision of levels of VEGF in pre operative-post operative and in controls.
Table  2  Serum level MMP-2, MMP-9, and VEGF in patients and control group.
Group Mean ± SD P value (pre vs post) P value (pre vs control)
MMP-2
Patient (pre OP) 833.90 ± 111.91 <0.001 <0.001
Patient (post OP) 553.02 ± 150.08
Control 228.33 ± 72.52
MMP-9
Patient (pre OP) 862.32 ± 119.77 <0.001 <0.001
Patient (post OP) 552.88 ± 151.91
Control 245.44 ± 116.52
VEGF














































Patient (post OP) 0.81 ± 0.32
Control 0.10 ± 0.04
tatistical  analysis
he study data presented as the mean and the standard deviation
nd analyzed with the statistical analysis software SPSS v20.0,
PSS corp. Elevated serum levels of MMP-2, MMP-9, and VEGF
efined in pre-operative levels above the 95th percentile of the dis-
ribution against post-operative and control subjects. Differences
ere evaluated using the Wilcoxon rank sum test, two-sample t-test,
NOVA and independent sample test for analyzing the level differ-
nce between pre and postoperative MMP-2, MMP-9, and VEGF
ith control. The Mann–Whitney U test (Kruskal–Wallis test) was
sed in evaluating the association case. The statistical significance
f paired differences between pre-treatment and follow-up was mea-
ured using the unpaired t-test. All p-values are two-tailed, no any
djustment did to compare other factors.
esults
atient  characteristics
he clinical data of 100 enrolled subjects abridged in Table 1, out
f 100 patients 71 (71%) were male and 29 (29%) were female.
he majority (84%) of patients were below age 65 and 39% of the
2 stage, 74% had clear cell histology, 60 out of 100 (60%) were
on-metastatic, other were metastatic most commonly involving the
ungs (13%). The majority number of the patients detected with big
umor of more than or equal to 7 cm size (60%), 57% of them were
on addicted apart from that 15% were addicted to tobacco chewing.




re-post-control  levels  of  MMP-2,  MMP-9  and  VEGF
n case of MMP-2,the result of levels achieved in preoperative renal
ell carcinoma patients was 833.90 ±  111.91 ng/ml (Mean ±  SD),
hich fall down in postoperative cases upto 553.02 ±  150.08 ng/ml
Mean ±  SD), while in control values obtained 28.33 ±  72.52 ng/ml
Mean ±  SD). The p-value of pre vs post was highly signif-
cant (0.001)-graphical comparison of levels can be seen in
ig. 1A. Similarly, in pre-operative cases of MMP-9, the level was
62.32 ±  119.77 ng/ml (Mean ±  SD), while, in post-operative this
evel drops down to 552.88 ±  151.91 ng/ml (Mean ±  SD), in con-
rol, the level was 245.44 ±  116.52 ng/ml (Mean ±  SD) The p-value
ound highly significant (P = 0.001 – see Fig. 1B).
n preoperative cases of VEGF, the level was 1.35 ±  0.36 ng/ml
Mean ±  SD) while, in postoperative cases the level was
.81 ±  0.46 ng/ml and in control group, the level found was
.10 ±  0.09, this result was also highly significant (P = 0.001 – see
ig. 1C).
ummary of result is in Table 2.
orrelation  between  tumor  grade  and  levels  of  MMP-2,  MMP-9
nd  VEGFhere is no correlation observed when MMP-2 (P  = 0.268), MMP-9
P  = 0.011), and VEGF (P  = 0.008) levels correlated with grade of
umor individually, i.e. low grade, intermediate and high grade with
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Figure  2  A(i) Correlation estimation between serum MMP-2 and grade of the tumor, in Fig. 2A(ii) correlation has been seen in case of MMP-
9 concentration and grade of the tumor, similarly in Fig. 2A(iii) correlation is seen between VEGF concentration and grade of the tumor. B(i)
Correlation estimation between serum MMP-2 and stage of the tumor. Fig. 2B(ii) correlation has been seen in case of MMP-9 concentration and
stage of the tumor. Fig. 2B (iii) correlation is seen between VEGF concentration and stage of the tumor. C(i) Correlation estimation between serum
MMP-2 and size of the tumor. Fig. 2C(ii) correlation has been seen in case of MMP-9 concentration and size of the tumor. Fig. 2C (iii) correlation
is seen between VEGF concentration and size of the tumor.  D(i) Correlation estimation between serum MMP-2 and size of the tumor. Fig. 2D(ii)
correlation has been seen in case of MMP-9 concentration and size of the tumor. Fig. 2D (iii) correlation is seen between VEGF concentration and
size of the tumor.
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Table  3  MMP-2, MMP-9 and VEGF correlation with tumor grade, stage, size and type.
Variable n MMP-2 (Sig) MMP-9 (Sig) VEGF (Sig)
Mean ± SD Mean ± SD Mean ± SD
Grade
Low grade 20 812.02 ± 102.60 (0.268) 791.97±  97.70 (0.011) 1.23 ± 0.31 (0.008)
Intermediate 46 825.35 ± 108.32 874.70 ± 115.83 1.28 ± 0.33
High grade + LN 34 858.34 ± 120.43 886.95 ± 124.12 1.50 ± 0.39
Stage
T1 28 828.97 ± 105.91 (0.264) 896.73 ± 115.93 (0.145) 1.30± 0.31 (0.433)
T2 39 859.06 ± 114.86 856.49 ± 102.02 1.35 ± 0.37
T3 22 801.40 ± 114.57 859.94 ± 152.11 1.45 ± 0.40
T4 + LN 11 822.27 ± 104.83 800.14 ± 99.30 1.27 ± 0.36
Size
≥7 cm 60 837.42 ± 124.79 (0.702) 877.45 ± 126.10 (0.122) 1.41 ± 0.38 (0.026)
<7 cm 40 828.63 ± 90.46 839.63 ± 107.13 1.25 ± 0.30
Cell type
Clear cell 74 820.36 ± 107.26 (0.134) 857.78 ± 125.69 (0.597) 1.33 ± 0.35 (0.478)
































































Chromophobe 06 907.95 ± 145.0 
Others 11 844.21 ± 117.10
ymph nodes (Fig. 2A.i–iii). Mann–Whitney U test (Kruskal–Wallis
est) used in evaluating the association case.
orrelation  between  tumor  stage  and  levels  of  MMP-2,  MMP-9
nd  VEGF
here is also no correlation was seen in the case of MMP-2
P  = 0.264), MMP-9 (P  = 0.145), and VEGF (P  = 0.433) levels when
ompared with stages of tumor like T1, T2, T3 and T4 + lymph nodes
Fig. 2B.i–iii), the output result suggests that higher or lower the
tage of tumor does not reflect a high density of MMP-2, MMP-9,
nd VEGF. Mann–Whitney U test (Kruskal–Wallis test) was used
n assessing the association.
orrelation  between  tumor  size  and  levels  of  MMP-2,  MMP-9  and
EGF
he correlation also checked through the Mann–Whitney U test
Kruskal–Wallis test) and here also found that there is no any cor-
elation in case of MMP-2 (P  = 0.702), MMP-9 (P  = 0.122), and
EGF (P  = 0.026) levels with size of i.e. tumor size less than 7 cm
nd size more than or equal to 7 cm (Fig. 2C.i–iii). Findings sug-
ested that more or less the size of the tumor could not summarize
he concentration of MMP-2, MMP-9 or VEGF within.
orrelation  between  tumor  size  and  levels  of  MMP-2,  MMP-9  and
EGF
o ensure any correlation the level of markers in patient serum and
umour cell type i.e clear cell, papillary, chromophobe and other
ypes of the tumor Mann–Whitney U  test (Kruskal–Wallis test)
pplied, we got no correlation result (MMP-2: P = 0.134, MMP-9:
 = 0.597, VEGF: P = 0.478), see Fig. 2D.i–iii.
he correlation observation was the secondary objective of the study
nd it suggests that no any association is embroiled with overex-
ression of MMP-2, MMP-9, and VEGF when they correlate with
arious types of tumor characteristics like tumor grade, stage, size





827.8 ± 77.22 1.43 ± 0.51
876.5 ± 93.67 1.49 ± 0.33
iscussion
n recent years, MMP’s and VEGF are the most talkable topic when
e are looking over various stages of cancer progression. In many
f the recent approach, MMP’s and VEGF action was inhibited by
sing synthetic inhibitors which seems to open a new era of cancer
reatment [17,18]. Annually, worldwide around 134,000 deaths are
eing recorded due to this disease [19].
t present, no any diagnostic method is available for initial diag-
osis of RCC, rather than detected incidentally sometimes during
ome routine tests or tests suggested for other means and similarly,
o modality is available to observe the recurrence or effectiveness
f treatment given. Biomarkers are easily quantifiable substances
hich can be used to surveil habitual as well as abnormal biological
unction. Lamentably, no existing biomarker is available till date for
etecting RCC. Throughout the course in current years, the salient
ole of MMPs and VEGF in diversified stages of cancer progression
orked over tremendously and found that obstructing the activity
f MMPs and VEGF using synthetic inhibitors could be a recent
pproach in the treatment of cancer [20].
mall molecule MMP and VEGF inhibitors like MMPI, marima-
tat, neovastat,prinomastat, and VGA 1155 have been studied in
dvanced phase clinical trials for the treatment of various types of
ancers [21–24].
ecently, some encouraging results received from clinical trials, in
hich synthetic anti MMP called synthetic MMPIs like marimastat
sed for treating advanced gastric cancer, temozolomide [25,26] for
reating recurrent and progressive glioblastoma multiforme has been
sed similarly anti VEGF were used in clinical trials and supports
DA to give approval for anti VEGF drugs like Clark et al. [27],
llis et al. [28] Yang et al. [29] etc.
lbeit about 300 differential proteins have been recognized from
arious renal tumor tests, cell lines or patient’s serum and from
heir particular controls by proteomic considers, but specified RCC
iomarkers have not been accessible for the detection and anticipa-


















































MMP-2, MMP-9 and VEGF in early prognosis of Renal cell carcin
In some studies, 3-azido withaferin-A induced MMP-2 inhibition
was found very much effective in the treatment of prostate cancer
and cervical cancer [31].
Sorafenib and Sunitinib which are orally administered tyrosine-
kinase inhibitor (TKI) which inhibit VEGFR for disease
management, they are widely using medicine for metastatic RCC
nowadays, these drugs are well tolerated and have significant disease
stabilizing activity and contribute in increasing progression-free sur-
vival (PFS) [32,33]. Some aggravating preliminary clinical retort
data with VEGF inhibition in RCC has provided a prospect for
treatment press forward for this historically resistant malignancy
[34].
Despite improving almost 5-year survival rates, clinicians and
researchers are looking for ways to better guide therapy by improv-
ing outcomes and limiting toxicities. New techniques in surgical
procedure and advancement in radiologic imaging are helping a lot
but, establishing and associating biomarker in treatment line, could
result in most accurate treatment on time when exactly required
and may give healthier treatment outcomes. Looking through all
prospective and the need of biomarkers in RCC we have gone
through many works of literature and observed that MMP-2, MMP-
9, and VEGF activity is found most active in RCC and, hence in this
paper we are trying to establish the role of MMP-2, MMP-9 and
VEGF as biomarker for prognosticating renal cell carcinoma in its
early stage.
Statistically, significantly higher level of MMP-2, MMP-9, and
VEGF was present in pre-operated patients when compared with
post-operated patients and controls.
Renal cell carcinoma introduces a diversified group of cancers that
come in existence from the proximal convoluted tubules of the
kidney. In comparison to other solid tumors, limited studies are
available for prognosticating the presence of renal cell carcinoma
in its early stage, for this reason, diagnosis is delayed and leads to a
huge number of disease-related deaths worldwide, the reason why
biomarkers are very much required to identify renal cell carcinoma
at an early stage.
MMP-2, MMP-9 and VEGF’s generally associated with pathways
creation for tumor generation, invasion and facilitate the tumor to
spread, in present work, we considered the levels of MMP-2, MMP-
9, and VEGF for diagnosing renal cell carcinoma in an early stage.
For the purpose serum sample of hundred patients of renal cell
carcinoma were collected before and after the surgery, conversely,
hundred control samples are collected from healthy kidney donors
before their surgery.
Pre and post-operative levels of patient MMP-2, MMP-9, and VEGF
compared individually and against control samples, furthermore,
according to result it is found that these biomarkers can help in
screening disease and detecting recurrence of RCC, and could be
helpful for starting the treatment in the early stage of diagnosis, to
increase progression-free and overall survival of the patient.
In addition to this, we have also studied that whether the levels have
any impact on the stage, grade, size, and type of the tumor.
Elevated serum MMP-2, MMP-9, and VEGF levels noted in RCC





ound associated with low progression-free and overall survival of
he patient. Taken as a whole, the results of our study positively pro-
ounding that MMP-2, MMP-9, and VEGF have important roles
rom initiation to the rapid progression of renal cell carcinoma and
herefore establishing a healthy reference range could be useful in
dentifying elevated levels and start treatment accordingly to stop
he development and progression of RCC. Though, a limited num-
er of patient and control in this study, some larger studies are
eeded to confirm our findings. Some more factors can be looked
hich we have not touched, like the level of MMP-2, MMP-9 and
EGF can be seen all together in patient serum, tissue and urine. In
onclusion, our findings provide substantiation that MMP-2, MMP-
, and VEGF together have important roles at different phases of
etastatic spread. Measurement of these markers in diagnostic as
ell as in follow up stages of the patient may be a milestone in
etecting RCC as well as for patients which are at high risk of
rogression.
onclusion
n summary, the present study has validated preliminary data show-
ng that circulating MMP-2, MMP-9, and VEGF are elevated in
atients with RCC and furthermore associated with poor prognosis.
e suppose it reflects an association between tumor progression and
levation of tumor-derived proteases which aggravates the disease.
urther characterization of MMP-2, MMP-9 and VEGF in humans,
s well as the results of enduring clinical trials, will help explicate
he role of MMP-2, MMP-9, and VEGF in patients with renal cell
arcinoma and its diagnosis in early stage and can be established as
iomarkers for better disease management and for achieving better
atient survival.
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